Open Actively Recruiting

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

About

Brief Summary

Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).

Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

Primary Purpose
Prevention
Study Type
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
19-002068
Category
Heart/Cardiovascular Diseases
Contact
Sucheta Waghmare
Location
  • UCLA Westwood
For Providers
NCT No.
NCT03907046
For detailed technical eligibility, visit ClinicalTrials.gov.